Avalo Therapeutics, Inc. short interest in 2022
In 2022, Avalo Therapeutics, Inc.'s disclosed short interest ran from 1.77% of shares outstanding on 14 Jan 2022 to 0.37% on 30 Dec 2022, a change of -1.40 percentage points. The year's high was 2.11% on 15 Jun 2022 and its low 0.36% on 15 Nov 2022, averaging 1.06% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.26 days on 31 May 2022. Full history: Avalo Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 1.77% (14 Jan 2022)
- End of year
- 0.37% (30 Dec 2022)
- Change
- -1.40 pp
- High
- 2.11% (15 Jun 2022)
- Low
- 0.36% (15 Nov 2022)
- Average
- 1.06%
- Highest days to cover
- 6.26 (31 May 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 1.77% | 1.74 | |
| 31 Jan 2022 | 1.34% | 2.10 | |
| 15 Feb 2022 | 1.12% | 4.58 | |
| 28 Feb 2022 | 1.26% | 3.27 | |
| 15 Mar 2022 | 1.25% | 3.65 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 1.28% | 5.52 | |
| 14 Apr 2022 | 1.52% | 4.21 | |
| 29 Apr 2022 | 1.84% | 5.35 | |
| 13 May 2022 | 1.84% | 2.57 | 10-Q filed, results (8-K) |
| 31 May 2022 | 1.91% | 6.26 | |
| 15 Jun 2022 | 2.11% | 4.14 | |
| 15 Aug 2022 | 0.93% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 0.56% | 2.50 | |
| 15 Sep 2022 | 0.71% | 1.69 | |
| 30 Sep 2022 | 0.47% | 3.98 | |
| 14 Oct 2022 | 0.52% | 3.58 | |
| 31 Oct 2022 | 0.37% | 2.16 | |
| 15 Nov 2022 | 0.36% | 1.19 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 0.40% | 5.62 | |
| 15 Dec 2022 | 0.43% | 5.03 | |
| 30 Dec 2022 | 0.37% | 2.69 |
See also: Avalo Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.